{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:46:40Z","timestamp":1791074800999,"version":"4.1.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aberrant expression of membrane mucins such as Muc1 and Muc4 by tumor cells has been shown to engage signaling pathways that promote cellular properties associated with tumor progression. Our previous studies have shown that Muc4 interacts with and potentiates signaling by the ErbB2 (HER2) receptor tyrosine kinase through an epidermal growth factor\u2013like domain in its extracellular region. Here, we show that expression of Muc4 in human A375 melanoma cells and MCF7 breast cancer cells confers resistance to apoptosis induced by a variety of stimuli, including chemotherapeutic agents, the absence of serum factors, and the loss of cellular adhesion. Mapping experiments revealed that the O-glycosylation and cytosolic domains of Muc4 are dispensable for its antiapoptotic activity, and are also dispensable for the potentiation of signaling by ErbB2. Knockdown of endogenous Muc4 in JIMT-1 breast cancer cells sensitizes cells to apoptotic stimuli, and this can be rescued by Muc4 forms lacking the O-glycosylation or cytosolic domains. Surprisingly, however, the molecular mechanisms underlying Muc4 antiapoptotic activity vary among cell lines. Although Muc4 in JIMT-1 cells engages ErbB2 to promote cell survival, its antiapoptotic mechanism in MCF7 and A375 cells seems to be independent of ErbB2. However, Muc4 expression in all cell lines culminates in the phosphorylation and inactivation of the proapoptotic protein Bad and the elevation of the prosurvival protein Bcl-xL. Our observations suggest that tumor cells can exploit the versatile antiapoptotic activities of Muc4 to acquire resistance to therapeutic agents, and augment cell survival after the loss of adhesion and microenvironment-derived survival factors. [Cancer Res 2009;69(7):2845\u201352]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2089","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T22:13:29Z","timestamp":1237328009000},"page":"2845-2852","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The Membrane Mucin Muc4 Inhibits Apoptosis Induced by Multiple Insults via ErbB2-Dependent and ErbB2-Independent Mechanisms"],"prefix":"10.1158","volume":"69","author":[{"given":"Heather C.","family":"Workman","sequence":"first","affiliation":[{"name":"UC Davis Cancer Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Sweeney","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Kermit L.","family":"Carraway","sequence":"additional","affiliation":[{"name":"UC Davis Cancer Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,1]]},"reference":[{"key":"2022061701473700500_B1","doi-asserted-by":"crossref","unstructured":"Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J\u20082008; 22: 966\u201381.","DOI":"10.1096\/fj.07-9673rev"},{"key":"2022061701473700500_B2","doi-asserted-by":"crossref","unstructured":"Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol\u20082008; 70: 431\u201357.","DOI":"10.1146\/annurev.physiol.70.113006.100659"},{"key":"2022061701473700500_B3","doi-asserted-by":"crossref","unstructured":"Carraway KL III, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol\u20082007; 78: 1\u201322.","DOI":"10.1016\/S0070-2153(06)78001-2"},{"key":"2022061701473700500_B4","doi-asserted-by":"crossref","unstructured":"Cullen PJ. Signaling mucins: the new kids on the MAPK block. Crit Rev Eukaryot Gene Expr\u20082007; 17: 241\u201357.","DOI":"10.1615\/CritRevEukarGeneExpr.v17.i3.50"},{"key":"2022061701473700500_B5","doi-asserted-by":"crossref","unstructured":"Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol\u20082006; 16: 467\u201376.","DOI":"10.1016\/j.tcb.2006.07.006"},{"key":"2022061701473700500_B6","doi-asserted-by":"crossref","unstructured":"Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol\u20082005; 18: 1295\u2013304.","DOI":"10.1038\/modpathol.3800445"},{"key":"2022061701473700500_B7","doi-asserted-by":"crossref","unstructured":"Kwon KY, Ro JY, Singhal N, et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med\u20082007; 131: 593\u20138.","DOI":"10.5858\/2007-131-593-MEINCL"},{"key":"2022061701473700500_B8","doi-asserted-by":"crossref","unstructured":"Karg A, Dinc ZA, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract\u20082006; 202: 577\u201383.","DOI":"10.1016\/j.prp.2006.04.002"},{"key":"2022061701473700500_B9","unstructured":"Giuntoli RL II, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Res\u20081998; 58: 5546\u201350."},{"key":"2022061701473700500_B10","doi-asserted-by":"crossref","unstructured":"Davidson B, Baekelandt M, Shih I. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol\u20082007; 35: 756\u201360.","DOI":"10.1002\/dc.20771"},{"key":"2022061701473700500_B11","doi-asserted-by":"crossref","unstructured":"Saitou M, Goto M, Horinouchi M, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol\u20082005; 58: 845\u201352.","DOI":"10.1136\/jcp.2004.023572"},{"key":"2022061701473700500_B12","doi-asserted-by":"crossref","unstructured":"Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg\u20082007; 14: 243\u201354.","DOI":"10.1007\/s00534-006-1169-2"},{"key":"2022061701473700500_B13","doi-asserted-by":"crossref","unstructured":"Miyahara N, Shoda J, Ishige K, et al. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer\u20082008; 44: 1048\u201356.","DOI":"10.1016\/j.ejca.2008.03.007"},{"key":"2022061701473700500_B14","doi-asserted-by":"crossref","unstructured":"Komatsu M, Carraway CA, Fregien NL, Carraway KL. Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. J Biol Chem\u20081997; 272: 33245\u201354.","DOI":"10.1074\/jbc.272.52.33245"},{"key":"2022061701473700500_B15","doi-asserted-by":"crossref","unstructured":"Komatsu M, Tatum L, Altman NH, Carothers Carraway CA, Carraway KL. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int J Cancer\u20082000; 87: 480\u20136.","DOI":"10.1002\/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6"},{"key":"2022061701473700500_B16","doi-asserted-by":"crossref","unstructured":"Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer\u20082002; 99: 783\u201391.","DOI":"10.1002\/ijc.10410"},{"key":"2022061701473700500_B17","doi-asserted-by":"crossref","unstructured":"Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res\u20082005; 65: 473\u201382.","DOI":"10.1158\/0008-5472.473.65.2"},{"key":"2022061701473700500_B18","unstructured":"Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res\u20081999; 59: 2229\u201336."},{"key":"2022061701473700500_B19","doi-asserted-by":"crossref","unstructured":"Komatsu M, Jepson S, Arango ME, Carothers Carraway CA, Carraway KL. Muc4\/sialomucin complex, an intramembrane modulator of ErbB2\/HER2\/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene\u20082001; 20: 461\u201370.","DOI":"10.1038\/sj.onc.1204106"},{"key":"2022061701473700500_B20","doi-asserted-by":"crossref","unstructured":"Carraway KL III, Rossi EA, Komatsu M, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem\u20081999; 274: 5263\u20136.","DOI":"10.1074\/jbc.274.9.5263"},{"key":"2022061701473700500_B21","doi-asserted-by":"crossref","unstructured":"Funes M, Miller JK, Lai C, Carraway KL III, Sweeney C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem\u20082006; 281: 19310\u20139.","DOI":"10.1074\/jbc.M603225200"},{"key":"2022061701473700500_B22","doi-asserted-by":"crossref","unstructured":"Cantley LC. The phosphoinositide 3-kinase pathway. Science\u20082002; 296: 1655\u20137.","DOI":"10.1126\/science.296.5573.1655"},{"key":"2022061701473700500_B23","doi-asserted-by":"crossref","unstructured":"Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol\u20081999; 1: E33\u20135.","DOI":"10.1038\/10026"},{"key":"2022061701473700500_B24","doi-asserted-by":"crossref","unstructured":"Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J\u20082008; 22: 954\u201365.","DOI":"10.1096\/fj.06-7859rev"},{"key":"2022061701473700500_B25","doi-asserted-by":"crossref","unstructured":"Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci\u20082006; 43: 1\u201367.","DOI":"10.1080\/10408360500295626"},{"key":"2022061701473700500_B26","doi-asserted-by":"crossref","unstructured":"Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science\u20081998; 281: 1322\u20136.","DOI":"10.1126\/science.281.5381.1322"},{"key":"2022061701473700500_B27","doi-asserted-by":"crossref","unstructured":"Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell\u20081995; 80: 285\u201391.","DOI":"10.1016\/0092-8674(95)90411-5"},{"key":"2022061701473700500_B28","doi-asserted-by":"crossref","unstructured":"Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem\u20081997; 272: 24101\u20134.","DOI":"10.1074\/jbc.272.39.24101"},{"key":"2022061701473700500_B29","doi-asserted-by":"crossref","unstructured":"Rossi EA, McNeer RR, Price-Schiavi SA, et al. Sialomucin complex, a heterodimeric glycoprotein complex. Expression as a soluble, secretable form in lactating mammary gland and colon. J Biol Chem\u20081996; 271: 33476\u201385.","DOI":"10.1074\/jbc.271.52.33476"},{"key":"2022061701473700500_B30","doi-asserted-by":"crossref","unstructured":"Tanner M, Kapanen AI, Junttila T, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther\u20082004; 3: 1585\u201392.","DOI":"10.1158\/1535-7163.1585.3.12"},{"key":"2022061701473700500_B31","doi-asserted-by":"crossref","unstructured":"Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus\/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A\u20081996; 93: 11400\u20136.","DOI":"10.1073\/pnas.93.21.11400"},{"key":"2022061701473700500_B32","doi-asserted-by":"crossref","unstructured":"Yen L, Cao Z, Wu X, et al. Loss of Nrdp1 enhances ErbB2\/ErbB3-dependent breast tumor cell growth. Cancer Res\u20082006; 66: 11279\u201386.","DOI":"10.1158\/0008-5472.CAN-06-2319"},{"key":"2022061701473700500_B33","doi-asserted-by":"crossref","unstructured":"Cullen PJ, Sabbagh WJ, Graham E, et al. A signaling mucin at the head of the Cdc42- and MAPK-dependent filamentous growth pathway in yeast. Genes Dev\u20082004; 18: 1695\u2013708.","DOI":"10.1101\/gad.1178604"},{"key":"2022061701473700500_B34","doi-asserted-by":"crossref","unstructured":"Shibahara H, Tamada S, Goto M, et al. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol\u20082004; 28: 327\u201338.","DOI":"10.1097\/00000478-200403000-00005"},{"key":"2022061701473700500_B35","doi-asserted-by":"crossref","unstructured":"Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol\u20082003; 65: 1419\u201325.","DOI":"10.1016\/S0006-2952(03)00086-8"},{"key":"2022061701473700500_B36","doi-asserted-by":"crossref","unstructured":"Baruch A, Hartmann M, Zrihan-Licht S, et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer\u20081997; 71: 741\u20139.","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<741::AID-IJC9>3.0.CO;2-R"},{"key":"2022061701473700500_B37","doi-asserted-by":"crossref","unstructured":"Passebosc-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res\u20082005; 11: 6862\u20137.","DOI":"10.1158\/1078-0432.CCR-05-0043"},{"key":"2022061701473700500_B38","doi-asserted-by":"crossref","unstructured":"Carraway KL, Ramsauer VP, Carraway CA. Glycoprotein contributions to mammary gland and mammary tumor structure and function: roles of adherens junctions, ErbBs and membrane MUCs. J Cell Biochem\u20082005; 96: 914\u201326.","DOI":"10.1002\/jcb.20612"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/7\/2845\/2623359\/2845.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/7\/2845\/2623359\/2845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:48:19Z","timestamp":1655441299000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/7\/2845\/553064\/The-Membrane-Mucin-Muc4-Inhibits-Apoptosis-Induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,4,1]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2089","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22381115.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499766.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499766","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381115","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}